McGill University today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative research projects in the area of lipid nanoparticles (LNPs). LNPs are critical components in mRNA medicines such as vaccines, as they are the primary delivery method of mRNA strands to the target cells.
Quebec says it will start using human papillomavirus tests as its primary screening tool for cervical cancer, replacing the Pap smear. The Health Department says the province will systematically offer HPV testing for cervical cancer screening to all women aged 25 to 65, every five years. Earlier this year, the Institut national d’excellence en santé et en services sociaux reported that the HPV test is more sensitive than a Pap smear and could allow patients to collect their own test samples.
Researchers seek to answer longstanding debate
- Regular cytology screening (pap or smear test) is still the most commonly used HPV screening method, and can prevent cancers up to age 75 years, although benefits decline with age
- For the newly introduced HPV DNA test, which offers a higher degree of accuracy, women aged 55 who have a negative test were predicted to be at low risk of cervical cancer
Being diagnosed with a malignant brain tumor is devastating news for patients and their loved ones. Whereas some types of tumor respond well to treatment, others such as glioblastomas – the most common and aggressive brain tumors – are known to recur and progress within short times from the diagnosis. Patients diagnosed with this type of cancer, and who undergo current standard treatment, have a median survival of 16 months.
Extensive population-based studies on a popular group of drugs used to treat type 2 diabetes revealed no association with acute pancreatitis, but increased risk of bile duct and gallbladder disease